# Effect of INtravenous FERRic Carboxymaltose Onmortality and Cardiovascular Morbidity, and Quality of Life in Iron Deficient Patients With Recent Myocardial infarCTion

Study · id `cardio:ct-nct05759078` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05759078](<https://clinicaltrials.gov/study/NCT05759078>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05759078

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1000 participants.

## Technical summary

Registry record NCT05759078. Randomized; triple masking; primary purpose treatment. Start 2022-09-22 (actual); primary completion 2026-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 1000 participants (planned count; ClinicalTrials.gov record NCT05759078, source copy `cardio:ctgov-nct05759078-2025-07-30`, retrieved 2026-10-26)
- Started: 2022-09-22 (actual) (ClinicalTrials.gov record NCT05759078, source copy `cardio:ctgov-nct05759078-2025-07-30`, retrieved 2026-10-26)
- Primary completion: 2026-12-31 (anticipated) (ClinicalTrials.gov record NCT05759078, source copy `cardio:ctgov-nct05759078-2025-07-30`, retrieved 2026-10-26)
- Completion: 2026-12-31 (anticipated) (ClinicalTrials.gov record NCT05759078, source copy `cardio:ctgov-nct05759078-2025-07-30`, retrieved 2026-10-26)
- Countries: Poland (ClinicalTrials.gov record NCT05759078, source copy `cardio:ctgov-nct05759078-2025-07-30`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05759078-2025-07-30`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effect of INtravenous FERRic Carboxymaltose Onmortality and Cardiovascular Morbidity, and Quality of Life in Iron Deficient Patients With Recent Myocardial infarCTion
- Acronym: INFERRCT
- Condition: Myocardial Infarction, Acute
- Intervention (Drug): Ferinject
- Intervention (Drug): Sodium Chloride 0.9% Inj
- Lead sponsor: Wroclaw Medical University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry lists this organization as the lead sponsor: Wroclaw Medical University (`cardio:org-wroclaw-medical-university`)

## Provenance

Content hash: 7b947dc8ffb28e4ad8b2fe0d0de6f97e17eec9fd83c8f8ef7f969d1836dfd199
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
